The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Sunitinib Krka 50 mg hard capsules



KRKA, d.d., Novo mestoPA1347/104/003

Main Information

Trade NameSunitinib Krka 50 mg hard capsules
Active SubstancesSunitinib
Dosage FormCapsule, hard
Licence HolderKRKA, d.d., Novo mesto
Licence NumberPA1347/104/003

Group Information

ATC CodeL01XE04 sunitinib

Status

License statusAuthorised
Licence Issued09/07/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Summary of Product Characteristics, section 4.2).
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable ListSunitinib 50mg Capsules
Interchangeable List CodeIC0147-023-001
Interchangeable List DocumentPDF of Interchangeable List
« Back